Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2013

01.05.2013 | Original Article

Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation

verfasst von: Anthony J. Michaels, Renumathy Dhanasekaran, David P. Foley, Ahmad Alkhasawneh, Lisa Dixon, Consuelo Soldevila-Pico, Giuseppe Morelli, Roniel Cabrera, Virginia C. Clark, Roberto J. Firpi

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Preservation injury in the HCV liver transplant population has been reported to correlate with poorer survival outcomes compared to preservation injury in the non-HCV liver transplant population. However, determinants of progression to cirrhosis in HCV infection remain poorly defined in this population.

Aim

This study aimed to determine if the presence and severity of preservation injury impact the acceleration of HCV recurrence and survival after liver transplant.

Methods

We retrospectively reviewed liver transplant HCV patients over a 10-year period. Biopsies from postoperative day 7 were assessed for preservation injury and 4- and 12-month biopsies were assessed for fibrosis. Patients with Ishak fibrosis >0.8 Units/year were considered rapid fibrosers.

Results

Our study group consisted of 255 patients. The mean age was 49.3 years old, 180 (70.6 %) were male, and 221 (86.7 %) were Caucasian. The incidence of preservation injury on the 7-day biopsy was 69.0 %. A strong correlation between postoperative peak AST within the first week and preservation injury was found. The overall prevalence of rapid fibrosers at 4 months, 1 and 2 years was 47.4, 75.2, and 58.9 %, respectively. The prevalence of rapid fibrosers at 4 months, 1 and 2 years between patients with or without preservation injury was not statistically significant (p = 0.39, p = 0.46, and p = 0.53, respectively). No differences were seen between patients with and without PI in terms of patient and graft survival.

Conclusion

In this study, the presence and severity of preservation injury were not associated with development of rapid HCV recurrence or worsening in survival.
Literatur
1.
Zurück zum Zitat Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMedCrossRef Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMedCrossRef
2.
Zurück zum Zitat Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1–16.PubMedCrossRef Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1–16.PubMedCrossRef
3.
Zurück zum Zitat Verna EC, Brown RS Jr. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis. 2008;12:637–659.PubMedCrossRef Verna EC, Brown RS Jr. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis. 2008;12:637–659.PubMedCrossRef
4.
Zurück zum Zitat Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1991;28:823–830.CrossRef Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1991;28:823–830.CrossRef
5.
Zurück zum Zitat Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl. 2009;15:1872–1881.PubMedCrossRef Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl. 2009;15:1872–1881.PubMedCrossRef
6.
Zurück zum Zitat Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–393.PubMedCrossRef Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384–393.PubMedCrossRef
7.
Zurück zum Zitat Manez R, Mateo R, Tabasco J, Kusne S, Starzl TE, Duquesnoy RJ. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation. 1995;59:640–642.PubMed Manez R, Mateo R, Tabasco J, Kusne S, Starzl TE, Duquesnoy RJ. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation. 1995;59:640–642.PubMed
8.
Zurück zum Zitat Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl. 2009;15:1783–1791.PubMedCrossRef Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl. 2009;15:1783–1791.PubMedCrossRef
9.
Zurück zum Zitat Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation. 1997;64:721–726.PubMedCrossRef Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation. 1997;64:721–726.PubMedCrossRef
10.
Zurück zum Zitat Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV− recipients. Transplantation. 2004;77:1834–1842.PubMedCrossRef Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV− recipients. Transplantation. 2004;77:1834–1842.PubMedCrossRef
11.
Zurück zum Zitat Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 2006;12:134–139.PubMedCrossRef Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 2006;12:134–139.PubMedCrossRef
12.
Zurück zum Zitat Lee YM, O’Brien CB, Yamashiki N, et al. Preservation injury patterns in liver transplantation associated with poor prognosis. Transplant Proc. 2003;35:2964–2966.PubMedCrossRef Lee YM, O’Brien CB, Yamashiki N, et al. Preservation injury patterns in liver transplantation associated with poor prognosis. Transplant Proc. 2003;35:2964–2966.PubMedCrossRef
13.
Zurück zum Zitat Tillery W, Demetris J, Watkins D, et al. Pathologic recognition of preservation injury in hepatic allografts with six months follow-up. Transplant Proc. 1989;21:1330–1331.PubMed Tillery W, Demetris J, Watkins D, et al. Pathologic recognition of preservation injury in hepatic allografts with six months follow-up. Transplant Proc. 1989;21:1330–1331.PubMed
14.
Zurück zum Zitat Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl. 2000;6:407–412.PubMedCrossRef Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl. 2000;6:407–412.PubMedCrossRef
15.
Zurück zum Zitat Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology. 1997;26:1513–1520.PubMedCrossRef Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology. 1997;26:1513–1520.PubMedCrossRef
16.
Zurück zum Zitat Selzner M, Camargo CA, Clavien PA. Ischemia impairs liver regeneration after major tissue loss in rodents: protective effects of interleukin-6. Hepatology. 1999;30:469–475.PubMedCrossRef Selzner M, Camargo CA, Clavien PA. Ischemia impairs liver regeneration after major tissue loss in rodents: protective effects of interleukin-6. Hepatology. 1999;30:469–475.PubMedCrossRef
17.
Zurück zum Zitat Brokelman W, Stel AL, Ploeg RJ. Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin solution era. Transplant Proc. 1999;31:2087–2090.PubMedCrossRef Brokelman W, Stel AL, Ploeg RJ. Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin solution era. Transplant Proc. 1999;31:2087–2090.PubMedCrossRef
18.
Zurück zum Zitat Busquets J, Figueras J, Serrano T, et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl. 2001;7:432–435.PubMedCrossRef Busquets J, Figueras J, Serrano T, et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl. 2001;7:432–435.PubMedCrossRef
19.
Zurück zum Zitat Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation. 1993;55:807–813.PubMedCrossRef Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation. 1993;55:807–813.PubMedCrossRef
20.
Zurück zum Zitat Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 1991;10:1240–1247.CrossRef Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 1991;10:1240–1247.CrossRef
21.
Zurück zum Zitat Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1991;22:696–699.CrossRef Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1991;22:696–699.CrossRef
22.
Zurück zum Zitat Killackey MT, Gondolesi GE, Liu LU, et al. Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation. Transplant Proc. 2008;40:1504–1510.PubMedCrossRef Killackey MT, Gondolesi GE, Liu LU, et al. Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation. Transplant Proc. 2008;40:1504–1510.PubMedCrossRef
23.
Zurück zum Zitat Shackleton CR, Martin P, Melinek J, et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. Transplantation. 1995;60:554–558.PubMedCrossRef Shackleton CR, Martin P, Melinek J, et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. Transplantation. 1995;60:554–558.PubMedCrossRef
24.
Zurück zum Zitat Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation. 2002;74:522–526.PubMedCrossRef Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation. 2002;74:522–526.PubMedCrossRef
25.
Zurück zum Zitat Boker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology. 1997;25:203–210.PubMed Boker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology. 1997;25:203–210.PubMed
Metadaten
Titel
Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation
verfasst von
Anthony J. Michaels
Renumathy Dhanasekaran
David P. Foley
Ahmad Alkhasawneh
Lisa Dixon
Consuelo Soldevila-Pico
Giuseppe Morelli
Roniel Cabrera
Virginia C. Clark
Roberto J. Firpi
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2521-9

Weitere Artikel der Ausgabe 5/2013

Digestive Diseases and Sciences 5/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.